Fintel reports that on February 7, 2025, Piper Sandler upgraded their outlook for Nevro (NYSE:NVRO) from Underweight to ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...

Globus Medical is acquiring Nevro Corp, a spinal cord stimulator company, according to a Feb. 6 news release. Globus Medical's transaction will include all shares of Nevro, which are valued at about ...

The first-in-human SCS trial saw all three SMA patients able to increase their walking distance within six minutes to 20 meters.

Spinal Cord Stimulators Market. The global spinal cord stimulators market is on an accelerated growth path, projected to ...

The Inceptiv data give Medtronic more evidence as it tries to increase sales of a product that drove double-digit growth at ...

Nevro NVRO is well-poised for growth in the coming quarters, courtesy of its business expansion plans and restructuring activities. The optimism, led by a decent preliminary full-year 2024 results, is ...

Nevro NVRO is well-poised for growth in the ... The company also received CE Mark Certification in Europe for its HFX iQ SCS system, integrating AI technology to enhance competitiveness and ...